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Abstract
Periampullary cancer is the term used for neoplasms arising from the head of pancreas, ampulla of Vater, distal bile 
duct and periampullary region of duodenum. Of these, the pancreatic adenocarcinoma carries the worst prognosis 
with majority of mortalities within the 1st year. The overall 5-year survival is <3%. Studies have shown that pancreatic 
carcinoma has the shortest median survival of 17.1 months of all periampullary carcinomas. With the development of 
metastasis, the median survival tends to reduce to 3–6 months. We are reporting a case of metastatic periampullary 
pancreatic adenocarcinoma that received minimal and interrupted chemotherapy due to poor tolerance and yet managed 
to survive far beyond the reported median survival.
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Introduction
Pancreatic adenocarcinoma is the most frequently 
occurring periampullary cancer, with an incidence of 9 
in 100,000 cancers in the US annually.[1-3]
Obstructive jaundice is the form of presentation in 
65–75% of patients while other presenting features may 
be pain, weight loss, anorexia, elevated liver enzymes 
and new-onset diabetes mellitus or pancreatitis.[2] 
Tumour marker Ca 19-9 may be helpful in diagnosis 
which in 75% of cases is raised. Diagnostic imaging 
includes computed tomography (CT) scan, magnetic 
resonance imaging scan, endoscopic retrograde 
pancreatocholangiography (ERCP) and endoscopic 
ultrasound (EUS) which also aids in obtaining tissue 
for histological diagnosis.[2,4]
Treatment options include pancreatoduodenectomy with 
intent to cure, leading to increase in 5-year survival. 
Palliative options include palliative surgery, endoscopic 
stenting and/or chemotherapy.[4] Locally advanced non-
metastatic periampullary pancreatic Ca has a median 
survival of 6–10 months.[5] However, in metastatic 
settings, median survival is a mere 3–6 months.[5,6]
Gemcitabine is the chemotherapeutic agent of choice in 
palliative settings which causes a modest but significant 
improvement in clinical condition and to some extent 
response and survival.[5,6]
In this paper, we present a case of an elderly lady 
diagnosed with metastatic periampullary pancreatic cancer 
who received suboptimal chemotherapy and managed to 
survive for 17 months after diagnosis. The case was chosen 
due to its unusual course and unexpectedly prolonged 
survival with minimal chemotherapy in metastatic 
settings.
Case Report
A 76-year-old female, known diabetic and hypertensive, 
presented to the gastroenterology clinic in September 
2014, with a history of fever, weight loss and jaundice 
over the preceding 3 months. On examination, she was 
deeply jaundiced and emaciated.
Her initial workup done before presentation to the hospital 
included a CT scan of the abdomen obtained in August 
2014, which showed biliary obstruction with suspicion of 
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4 mm non-calcified calculus at the level of ampulla. Her 
ERCP revealed periampullary pancreatic carcinoma and 
duodenal ulcer. Biopsy was taken which was positive for 
well-differentiated adenocarcinoma [Figure 1].
Her CT scan was repeated at our hospital which was 
suggestive of intra- and extra-hepatic biliary dilatation 
with dilated pancreatic duct traceable all the way up 
to the ampulla and presence of pulmonary metastasis 
making it a Stage IV disease [Figure 2]. However, EUS 
was recommended for further assessment.
EUS was done which showed 25 mm × 16 mm mass at the 
lower end of the common bile duct/in the periampullary 
region and a local node of 10 mm. The patient was 
discussed in MDT and recommendations were ERCP 
with metallic stent insertion followed by chemotherapy 
gemcitabine with 25% dose reduction. The patient 
received two cycles of gemcitabine, but due to fatigue and 
anorexia, her regime was switched to capecitabine. After 
receiving one cycle of capecitabine, she was lost to follow-
up. Her last visit to the hospital was in December 2014.
The patient resurfaced in October 2015 with fever, itching 
and vomiting, obstructive jaundice and raised lipase levels. 
She was treated on lines of cholangitis and pancreatitis 
with intravenous piptazobactam.
CT scan was repeated for restaging purposes and it showed 
progression in primary disease and appearance of hepatic 
metastasis [Figure 3].
Her blocked stent was replaced and she was discharged 
from the hospital in a stable clinical condition with 
improving liver function tests. She passed away in 
December 2015, 16 months after diagnosis and 12 months 
of no treatment for primary disease.
Figure 1: (×4) A fragment of duodenal mucosa. The overlying 
epithelium shows ulceration and erosion with a dense 
inflammatory infiltrate. A tumour is seen infiltrating through the 
muscularis mucosae into the lamina propria
Figure 2: Baseline computed tomography scan showing lung 
metastasis (blue arrow)
Figure 3: Computed tomography scan repeated after a year 
showed the presence of liver metastasis (blue arrows) consistent 
with disease progression
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Discussion
Periampullary tumours are defined as those tumours that 
arise within 2 cm of the major papilla in the duodenum 
and include pancreatic adenocarcinoma, distal bile duct 
and periampullary duodenal carcinomas.[1,4,7] Ampullary 
carcinomas lie in the region of ampulla of Vater and 
account for about 0.2% of tumours of the gastrointestinal 
tract and 6% of periampullary malignancies.[1,7] Clinically, 
it is important to distinguish between ampullary and 
periampullary tumours due to the significance, it imparts 
to the prognosis and resectability.[1] Ampullary carcinomas 
carry a better prognosis[1,7] with 5-year survival ranging 
from 34 to 45%.[1]
Most of the patients with pancreatic adenocarcinoma 
present at a late stage and carry a poor prognosis.[1] 
Resectability is possible in only 15% of cases which 
increases the long-term survival in almost 25% of 
patients.[8] 95% of patients usually die within a year and 
5-year survival after a curative surgery is only 5–20%, 
thus making pancreatic adenocarcinoma the worst of 
periampullary cancers.[1] Metastatic periampullary 
pancreatic malignancy has a much lower median survival 
of 3–6 months.[6]
Commonly periampullary pancreatic adenocarcinoma 
presents with jaundice and abdominal pain. Other non-
specific symptoms are weight loss and anorexia. New-
onset diabetes mellitus is also one form of presentation.[2,8]
Mostly periampullary tumours are adenocarcinomas.[4] 
Radiological workup for pancreatic malignancy includes 
a CT scan which usually suggests the diagnosis in 95% of 
the cases. In periampullary tumours, endoscopic retrograde 
cholangiopancreatography is a part of diagnostic workup. 
It has a therapeutic role as well in case of obstructive 
symptoms with a stent placement.[8] Endoscopic ultrasound 
has a role in staging workup by assessing the depth of 
invasion and involvement of peripancreatic lymph nodes 
along with obtaining fine-needle aspiration and brushings 
for cytology.[4] Amongst the treatment modalities, surgical 
resection of periampullary malignancies is the only 
possible way of improving long-term survival; however, 
the resectability rate for pancreatic cancer is as low as 
20%.[1]
Metastatic pancreatic cancer is associated with poor 
prognosis and low median survival of 3–6 months. 
Treatment of metastatic pancreatic cancer remains a 
challenge. The standard cytotoxic agent is gemcitabine. 
Although response rate is poor, it has shown clinical 
benefit in improving quality of life.[6,9] Patients treated with 
gemcitabine have a median survival of 6.2 months and a 
1-year survival of 20%.[10] Combinations of gemcitabine 
with several other chemotherapeutic agents such as 
capecitabine, irinotecan, cisplatin or oxaliplatin have been 
studied in trials and have not shown any major advantage 
in survival.[9,10]
A combination of gemcitabine and epidermal growth 
factor tyrosine kinase inhibitor erlotinib has been approved 
by the Food and Drug Authority due to a significant long-
term survival advantage.[10]
Review of literature clearly indicates a very low 
median survival associated with metastatic pancreatic 
periampullary malignancy even with chemotherapy. In 
case of our patient, she received interrupted chemotherapy 
and yet survived for 16 months after diagnosis and 
12 months with no treatment whatsoever which was 
quite extraordinary. The prognosis for periampullary 
carcinoma in the resected patient is better than pancreatic 
adenocarcinoma, but in case of metastatic disease, the 
outcome is dismal. This particular case highlights the 
fact that there is indeed number of patients that might 
abate the need for cytotoxic chemotherapy and the related 
side effects. So far, there is/are no prognostic factor/s 
discovered which can be utilised to tailor treatment to 
each patient individually.
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